Mark Bouzyk, PhD will serve as the Genetics Core Director. Dr. Bouzyk is the director of the Emory Center for Medical Genomics (CMG), which will house and administer the Genetics Core. The core provides state-of-theart laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk recently joined the faculty at Emory with a more than eight year track record in a global pharmaceutical company, GlaxoSmithKline, where he served as Director of Genetic Laboratory Sciences leading the company's high throughput genotyping efforts in Europe. During his time in industry, Dr Bouzyk not only established and managed the high throughput genetic laboratories for GSK, including DMA sample management, sequencing and genotyping, he also delivered key processes for candidate gene and whole genome association studies as well as negotiating key scientific &technological agreements for such genetic projects. This has resulted in an annual turnover of more than 10 million genotypes at GSK with significant preliminary association data in several common diseases, such as diabetes and asthma. In his position at Emory, Dr. Bouzyk serves as the link between the faculty utilizing the services of the core and the technicians analyzing the samples. Under his direction, the Center for Medical Genomics has acquired the equipment and personnel necessary to operate as a high-throughput extraction, sequencing, expression and genotyping facility. Dr. Bouzyk is responsible for working with the faculty to develop workflows for the life cycle of each project, to develop methods to ensure high quality of the data produced by the core, and to identify and acquire new technology and equipment.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Center Core Grants (P30)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Seyfried, Nicholas T; Dammer, Eric B; Swarup, Vivek et al. (2016) A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Cell Syst :
Wigington, Callie P; Morris, Kevin J; Newman, Laura E et al. (2016) The Polyadenosine RNA-binding Protein, Zinc Finger Cys3His Protein 14 (ZC3H14), Regulates the Pre-mRNA Processing of a Key ATP Synthase Subunit mRNA. J Biol Chem 291:22442-22459
Gentry, Erik G; Henderson, Benjamin W; Arrant, Andrew E et al. (2016) Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration. J Neurosci 36:1316-23
Henderson, Benjamin W; Gentry, Erik G; Rush, Travis et al. (2016) Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain. J Neurochem 138:525-31
Arnold, Miranda; Cross, Rebecca; Singleton, Kaela S et al. (2016) The Endosome Localized Arf-GAP AGAP1 Modulates Dendritic Spine Morphology Downstream of the Neurodevelopmental Disorder Factor Dysbindin. Front Cell Neurosci 10:218
Gourley, Shannon L; Zimmermann, Kelsey S; Allen, Amanda G et al. (2016) The Medial Orbitofrontal Cortex Regulates Sensitivity to Outcome Value. J Neurosci 36:4600-13
Mariani, Laura E; Bijlsma, Maarten F; Ivanova, Anna I et al. (2016) Arl13b regulates Shh signaling from both inside and outside the cilium. Mol Biol Cell :
Gutekunst, Claire-Anne; Tung, Jack K; McDougal, Margaret E et al. (2016) C3 transferase gene therapy for continuous conditional RhoA inhibition. Neuroscience 339:308-318
Nioi, Paul; Sigurdsson, Asgeir; Thorleifsson, Gudmar et al. (2016) Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. N Engl J Med 374:2131-41
Song, SungWon; Miranda, Carlos J; Braun, Lyndsey et al. (2016) Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat Med 22:397-403

Showing the most recent 10 out of 196 publications